Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of federal price negotiations, which are scheduled to begin this year, with resulting bargained prices going into effect in 2027.
The first round of negotiations, involving 10 high-cost drugs, wrapped up in August, with resulting prices being 38 percent to 79 percent lower than list prices. Those negotiated prices will go into effect in 2026 and are expected to save people with Medicare prescription drug coverage $1.5 billion in out-of-pocket costs.
“Last year we proved that negotiating for lower drug prices works,” Xavier Becerra, secretary of the Department of Health and Human Services (HHS), said in a statement. “Now we plan to build on that record by negotiating for lower prices for 15 additional important drugs for seniors.”